DSA is a Finnish health care technology company, whose novel BreathPass™ analyzing device and COVID-19 test revolutionize large-scale community-based COVID-19 screening with a low-cost, non-invasive, and highly accurate COVID test. DSA BreathPass™ COVID-19 test sets a new standard for efficiently screening large groups with industry-leading “real-time” test results.
DSA is an innovative, growth-oriented, and globally minded company. We are passionate about creating an intelligent, AI-powered technology that can scale to address the world’s growing demand for real-time screening. We are driven to provide a disruptive COVID screening solution that helps individuals, families, and communities return to normal at work, school, and play.
Our main product, DSA BreathPass™ is a handheld device intended for rapid screening of large numbers of people to provide presumptive negative results of COVID-19 infection. Inside the device there is an array of nano-sensors to detect molecules of biological origin, known as volatile organic compounds (VOC), as signs of infection stemming from the biomarkers known to be produced by the metabolic processes caused by the SARS-CoV-2 virus.
DSA will continue to investigate opportunities to widen the analysis of exhaled breath as an indicator for severe diseases. With our state-of-the-art DSA BreathPassTM analyzing device we feel it is possible to come up with solutions for the early indication of developing lung cancer, colon cancers, pneumonia to name a few. We actively look at research and development partners who would like to participate in the future of medical science. Let us know what would be your angle of interest.
Please take a look at our website for more details and datasheets.
